精華製藥(002349.SZ)業績快報:2020年度業績扭虧為盈至1.11億元
格隆匯 2 月 25日丨精華製藥(002349.SZ)披露2020年度業績快報,實現營業總收入12.84億元,同比增長10.90%;營業利潤5976.77萬元;利潤總額5902.86萬元;歸屬於上市公司股東淨利潤1.11億元,上年同期虧損3.94億元;基本每股收益0.1368元。
2020年,面對全球新冠疫情和複雜多變的國內外經營環境,公司積極採取措施一方面做好疫情防控工作,一方面積極開拓市場,有效應對了新冠疫情帶來的挑戰,2020年度實現歸屬於上市公司股東的淨利潤1.11億元,同比增長128.30%,主要原因系去年同期計提商譽減值等資產減值損失較多。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.